HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only appendix All Versions of this Article: thx.2008.098244v1 63/11/981    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Tata, L J Articles by Hubbard, R B PubMed PubMed Citation Articles by Tata, L J Articles by Hubbard, R B Topic Collections Epidemiologic studies General practice / family medicine Child health Asthma Drugs: respiratory system Relevant Articles

Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study

¹ Epidemiology & Public Health, University of Nottingham, UK
² Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, UK

Correspondence to:
Dr L J Tata, Division of Epidemiology & Public Health, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; laila.tata{at}nottingham.ac.uk

Background: Clinical advice to pregnant women with asthma is to maintain optimal therapeutic management; however, potential adverse effects of asthma treatments on fetal development remain uncertain. A study was undertaken to assess the association between maternal asthma and gestational exposure to asthma medications with risk of congenital malformation in offspring.

Methods: A matched case-control study was performed using The Health Improvement Network primary care database. Children with malformations were matched to control children on birth year, general practice and singleton or twin delivery.

Results: 5124 cases of liveborn children with major congenital malformations and 30 053 controls were included in the study. The risk of any malformation in children born to women with asthma was marginally higher than that in children born to women without asthma (adjusted OR 1.10, 95% CI 1.01 to 1.20). However, no association was present in children born to mothers receiving asthma treatment in the year before or during pregnancy (OR 1.06, 95% CI 0.94 to 1.20). In assessing teratogenicity of medications, no increased risk of malformation was found with gestational exposures to short- or long-acting β agonists, inhaled corticosteroids, oral corticosteroids, other bronchodilators or cromones. These findings were similar for each of 11 system-specific malformation groups, except for an increase in musculo-skeletal system malformation associated with cromone exposure.

Conclusions: Gestational exposure to commonly used asthma medications was found to be safe overall, although a moderate teratogenic risk of cromones cannot be excluded. There was some evidence of a small increased risk of congenital malformation in children born to women with asthma, but this was not explained by gestational exposure to asthma drugs.

This article has been cited by other articles:

				M. Cazzola and M. G. Matera Treatment of asthma during pregnancy: more solid evidence needed Thorax, November 1, 2008; 63(11): 944 - 945. [Full Text] [PDF]